Mathias Schmidt
Directeur/Bestuurslid bij JCR PHARMACEUTICALS CO., LTD.
Actieve functies van Mathias Schmidt
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Directeur/Bestuurslid | 01-06-2020 | - |
| Corporate Officer/Principal | 01-06-2020 | - | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Directeur/Bestuurslid | 01-10-2016 | - |
| Algemeen Directeur | - | - | |
| JCR USA, Inc. | Algemeen Directeur | - | - |
| President | - | - |
Loopbaan van Mathias Schmidt
Opleiding van Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Statistieken
Internationaal
| Duitsland | 3 |
| Verenigde Staten | 3 |
| Japan | 2 |
Operationeel
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
- Beurs
- Insiders
- Mathias Schmidt
- Ervaring
